Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry

Noriaki Moriyama; Teemu Laakso; Fausto Biancari; Peter Raivio; Maina P. Jalava; Jussi Jaakkola; Sebastian Dahlbacka; Eeva-Maija Kinnunen; Tatu Juvonen; Annastiina Husso; Matti Niemela; Tuomas Ahvenvaara; Tuomas Tauriainen; Marko Virtanen; Pasi Maaranen; Markku Eskola; Stefano Rosato; Timo Makikallio; Mikko Savontaus; Antti Valtola; Vesa Anttila; Juhani Airaksinen; Mika Laine

doi:10.4244/EIJ-D-19-00247

Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry

Noriaki Moriyama, Teemu Laakso, Fausto Biancari, Peter Raivio, Maina P. Jalava, Jussi Jaakkola, Sebastian Dahlbacka, Eeva-Maija Kinnunen, Tatu Juvonen, Annastiina Husso, Matti Niemela, Tuomas Ahvenvaara, Tuomas Tauriainen, Marko Virtanen, Pasi Maaranen, Markku Eskola, Stefano Rosato, Timo Makikallio, Mikko Savontaus, Antti ValtolaVesa Anttila, Juhani Airaksinen, Mika Laine

Istituto Superiore di Sanita'

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: The aim of this study was to compare the risk of prosthetic valve endocarditis (PVE) in patients with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Methods and results: The FinnValve registry included data from 6,463 consecutive patients who underwent TAVR (n=2,130) or SAVR (n=4,333) with a bioprosthesis from 2008 to 2017. PVE was defined according to the modified Duke criteria. In this study, the incidence of PVE was 3.4/1,000 person-years after TAVR, and 2.9/1,000 person-years after SAVR. In competing risk analysis there was no significant difference in the risk of PVE between patients with TAVR and SAVR over an eight-year observational period. Male gender (HR 1.73, 95 1.04-2.89) and deep sternal wound infection or vascular access-site infection (HR 5.45, 95 2.24-13.2) were positively associated with PVE, but not type of procedure (HR 1.09, 95 0.59-2.01) in multivariate analysis. The mortality rate was 37.72.5hospital mortality (HR 0.34, 95 0.21-0.61). Conclusions: PVE is rare, and its risk is similar after TAVR and SAVR.

Original language	English
Pages (from-to)	E499+
Journal	EuroIntervention
Volume	15
Issue number	6
DOIs	https://doi.org/10.4244/EIJ-D-19-00247
Publication status	Published - Aug 1 2019

Keywords

Prosthetic valve
endcarditis
TAVI
surgical valve replacement
bioprosthesis

Access to Document

10.4244/EIJ-D-19-00247

Cite this

Moriyama, N., Laakso, T., Biancari, F., Raivio, P., Jalava, M. P., Jaakkola, J., Dahlbacka, S., Kinnunen, E-M., Juvonen, T., Husso, A., Niemela, M., Ahvenvaara, T., Tauriainen, T., Virtanen, M., Maaranen, P., Eskola, M., Rosato, S., Makikallio, T., Savontaus, M., ... Laine, M. (2019). Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry. EuroIntervention, 15(6), E499+. https://doi.org/10.4244/EIJ-D-19-00247

Moriyama, N, Laakso, T, Biancari, F, Raivio, P, Jalava, MP, Jaakkola, J, Dahlbacka, S, Kinnunen, E-M, Juvonen, T, Husso, A, Niemela, M, Ahvenvaara, T, Tauriainen, T, Virtanen, M, Maaranen, P, Eskola, M, Rosato, S, Makikallio, T, Savontaus, M, Valtola, A, Anttila, V, Airaksinen, J & Laine, M 2019, 'Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry', EuroIntervention, vol. 15, no. 6, pp. E499+. https://doi.org/10.4244/EIJ-D-19-00247

@article{2144d9f468d14e23a1aa71d9c973676e,

title = "Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry",

abstract = "Aims: The aim of this study was to compare the risk of prosthetic valve endocarditis (PVE) in patients with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Methods and results: The FinnValve registry included data from 6,463 consecutive patients who underwent TAVR (n=2,130) or SAVR (n=4,333) with a bioprosthesis from 2008 to 2017. PVE was defined according to the modified Duke criteria. In this study, the incidence of PVE was 3.4/1,000 person-years after TAVR, and 2.9/1,000 person-years after SAVR. In competing risk analysis there was no significant difference in the risk of PVE between patients with TAVR and SAVR over an eight-year observational period. Male gender (HR 1.73, 95 1.04-2.89) and deep sternal wound infection or vascular access-site infection (HR 5.45, 95 2.24-13.2) were positively associated with PVE, but not type of procedure (HR 1.09, 95 0.59-2.01) in multivariate analysis. The mortality rate was 37.72.5hospital mortality (HR 0.34, 95 0.21-0.61). Conclusions: PVE is rare, and its risk is similar after TAVR and SAVR.",

keywords = "Prosthetic valve, endcarditis, TAVI, surgical valve replacement, bioprosthesis",

author = "Noriaki Moriyama and Teemu Laakso and Fausto Biancari and Peter Raivio and Jalava, {Maina P.} and Jussi Jaakkola and Sebastian Dahlbacka and Eeva-Maija Kinnunen and Tatu Juvonen and Annastiina Husso and Matti Niemela and Tuomas Ahvenvaara and Tuomas Tauriainen and Marko Virtanen and Pasi Maaranen and Markku Eskola and Stefano Rosato and Timo Makikallio and Mikko Savontaus and Antti Valtola and Vesa Anttila and Juhani Airaksinen and Mika Laine",

year = "2019",

month = aug,

day = "1",

doi = "10.4244/EIJ-D-19-00247",

language = "English",

volume = "15",

pages = "E499+",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "EuroPCR",

number = "6",

}

TY - JOUR

T1 - Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry

AU - Moriyama, Noriaki

AU - Laakso, Teemu

AU - Biancari, Fausto

AU - Raivio, Peter

AU - Jalava, Maina P.

AU - Jaakkola, Jussi

AU - Dahlbacka, Sebastian

AU - Kinnunen, Eeva-Maija

AU - Juvonen, Tatu

AU - Husso, Annastiina

AU - Niemela, Matti

AU - Ahvenvaara, Tuomas

AU - Tauriainen, Tuomas

AU - Virtanen, Marko

AU - Maaranen, Pasi

AU - Eskola, Markku

AU - Rosato, Stefano

AU - Makikallio, Timo

AU - Savontaus, Mikko

AU - Valtola, Antti

AU - Anttila, Vesa

AU - Airaksinen, Juhani

AU - Laine, Mika

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Aims: The aim of this study was to compare the risk of prosthetic valve endocarditis (PVE) in patients with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Methods and results: The FinnValve registry included data from 6,463 consecutive patients who underwent TAVR (n=2,130) or SAVR (n=4,333) with a bioprosthesis from 2008 to 2017. PVE was defined according to the modified Duke criteria. In this study, the incidence of PVE was 3.4/1,000 person-years after TAVR, and 2.9/1,000 person-years after SAVR. In competing risk analysis there was no significant difference in the risk of PVE between patients with TAVR and SAVR over an eight-year observational period. Male gender (HR 1.73, 95 1.04-2.89) and deep sternal wound infection or vascular access-site infection (HR 5.45, 95 2.24-13.2) were positively associated with PVE, but not type of procedure (HR 1.09, 95 0.59-2.01) in multivariate analysis. The mortality rate was 37.72.5hospital mortality (HR 0.34, 95 0.21-0.61). Conclusions: PVE is rare, and its risk is similar after TAVR and SAVR.

AB - Aims: The aim of this study was to compare the risk of prosthetic valve endocarditis (PVE) in patients with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Methods and results: The FinnValve registry included data from 6,463 consecutive patients who underwent TAVR (n=2,130) or SAVR (n=4,333) with a bioprosthesis from 2008 to 2017. PVE was defined according to the modified Duke criteria. In this study, the incidence of PVE was 3.4/1,000 person-years after TAVR, and 2.9/1,000 person-years after SAVR. In competing risk analysis there was no significant difference in the risk of PVE between patients with TAVR and SAVR over an eight-year observational period. Male gender (HR 1.73, 95 1.04-2.89) and deep sternal wound infection or vascular access-site infection (HR 5.45, 95 2.24-13.2) were positively associated with PVE, but not type of procedure (HR 1.09, 95 0.59-2.01) in multivariate analysis. The mortality rate was 37.72.5hospital mortality (HR 0.34, 95 0.21-0.61). Conclusions: PVE is rare, and its risk is similar after TAVR and SAVR.

KW - Prosthetic valve

KW - endcarditis

KW - TAVI

KW - surgical valve replacement

KW - bioprosthesis

U2 - 10.4244/EIJ-D-19-00247

DO - 10.4244/EIJ-D-19-00247

M3 - Article

SN - 1774-024X

VL - 15

SP - E499+

JO - EuroIntervention

JF - EuroIntervention

IS - 6

ER -

Prosthetic valve endocarditis after transcatheter or surgical aortic valve replacement with a bioprosthesis: results from the FinnValve Registry

Abstract

Keywords

Access to Document

Fingerprint

Cite this